Cytotoxic T-lymphocyte escape viral variants: How important are they in viral evasion of immune clearance in viyo?

Immunological Reviews

Volumn 164, Issue , 1998, Pages 37-51

  Borrow, Persephone ^a   Shaw, George M ^b  

^a EDWARD JENNER INST FOR VACC RES   (United Kingdom)

^b University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; EPITOPE; VIRUS PROTEIN;

ANTIGEN RECOGNITION; ARTICLE; CLEARANCE; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOPATHOGENESIS; NONHUMAN; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; VIRUS INFECTION; VIRUS REPLICATION;

AMINO ACID SEQUENCE; ANTIGENIC VARIATION; ANTIGENS, VIRAL; EVOLUTION, MOLECULAR; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC; VIRUS DISEASES;

EID: 0031756745     PISSN: 01052896     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-065X.1998.tb01206.x     Document Type: Article

References (115)

1. Ahmed R, Morrison LA, Knipe DM. Viral persistence. In: Nathanson N, ed. Viral pathogenesis. Philadelphia: Lippincott-Raven Publishers; 1997. p.181-205.
2. Spriggs MK. One-step ahead of the game - viral immunomodulatory molecules. Annu Rev Immunol 1996;14:101-130.
3. Griffin DE. Virus-induced immune suppression. In: Nathanson NA, ed. Viral pathogenesis. Philadelphia: Lippincott-Raven Publishers; 1997. p.207-233.
4. Planz O, Seiler P, Hengartner H, Zinkernagel RM. Specific cytotoxic T cells eliminate cells producing neutralizing antibodies. Nature 1996;381:726-729.
5. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993;362:758-761.
6. Stevens JG. Overview of herpesvirus latency. Semin Virol 1994;5:191-196.
7. Lipton HL, Gilden DH. Viral diseases of the nervous system: persistent infections. In: Nathanson NA, ed. Viral pathogenesis. Philadelphia: Lippincott-Raven Publishers; 1997. p.855-869.
8. Wiertz EJHJ, Mukherjee S, Ploegh HL. Viruses use stealth technology to escape from the host immune system. Mol Med Today 1997;3:116-123.
9. Wiley DC, Wilson IA, Skehel JJ. Structural identification of the antibody-binding sites of Hong Kong influenza hemagglutinin and their involvement in antigenic variation. Nature 1981;289:373-378.
10. Pircher H, Moskophidis D, Rohrer U, Burki K, Hengartner H, Zinkernagel RM. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990;346:629-633.
11. Koup RA. Virus escape from CTL recognition. J Exp Med 1994;180:779-782.
12. Oldstone MBA. How viruses escape from cytotoxic T lymphocytes: molecular parameters and players. Virology 1997;234:179-185.
13. Del Val M, Schlicht H-J, Ruppert T, Reddehase MJ, Koszinowski UH. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. Cell 1991;66:1145-1153.
14. Eisenlohr LC, Yewdell JW, Bennink JR. Flanking sequences influence the presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J Exp Med 1992;175:481-487.
15. Couillin I, et al. Impaired cytotoxic T lymphocyte recognition due to genetic variations in the main immunogenic region of the human immunodeficiency virus 1 NEF protein. J Exp Med 1994;180:1129-1134.
16. Ossendorp F, et al. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Immunity 1996;5:115-124.
17. Green WR, Smith PM. Endogenous ecotropic and recombinant MCF mouse retroviral variation and escape from antiviral CTL. Semin Virol 1996;7:49-60.
18. McMichael AJ, Phillips RE. Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 1997; 15:271-296.
19. De Campos-Lima P-O, et al. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population. Science 1993;260:98-100.
20. De Campos-Lima P-O, Levitskaya J, Frisan T, Masucci MG. Strategies of immunoescape in Epstein-Barr virus persistence and pathogenesis. Semin Virol 1996;7:75-82.
21. Reid SW, et al. Antagonist HIV-1 Gag peptides induce structural changes in HLA B8. J Exp Med 1996;184:2279-2286.
22. Evavold B, Sloan-Lancaster J, Allen P. Tickling the TCR: selective T cell functions stimulated by APL. Immunol Today 1993;14:602-609.
23. Jameson SC, Bevan MJ. T cell receptor antagonists and partial antagonists. Immunity 1995;2:1-11.
24. Sloan-Lancaster J, Shaw A, Rothbard J, Allen P. Partial T cell signalling: altered phosho-zeta and lack of Zap- 70 recruitment in APL-induced T cell anergy. Cell 1994;79:931-942.
25. Madrenas J, Wange R, Wang J, Samelson L, Germain R. Zeta phosphorlyation without zap 70 activation induced by TCR antagonists or partial agonists. Science 1995;267:515-519.
26. Sloan-Lancaster J, Allen PM. Altered peptide ligand-induced partial T cell activation: molecular mechanisms and role in T cell biology. Annu Rev Immunol 1996;14:1-27.
27. Klenerman P, Meier U-C, Phillips RE, McMichael AJ. The effects of natural altered peptide ligands on the whole blood cytotoxic T lymphocyte response to human immunodeficiency virus. Eur J Immunol 1995;25:1927-1931.
28. Sloan-Lancaster J, Evavold B, Allen P. Induction of T cell anergy by altered TCR ligand on live APCs. Nature 1993;363:156-159.
29. Jameson SC, Carbone FR, Bevan MJ. Clone-specific T cell receptor antagonists of major histocompatiblity class I-restricted cytotoxic T cells. J Exp Med 1993;177:1541-1550.
30. Bertoletti A, et al. Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature 1994;369:407-410.
31. Klenerman P, et al. Cytotoxic T-cell activity antagonized by naturally occurring HIV-1 Gag variants. Nature 1994;369:403-407.
32. Steinhauer DA, Domingo E, Holland JJ. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 1992;122:281-288.
33. Domingo E, Holland JJ. RNA virus mutations and fitness for survival. Annu Rev Microbiol 1997;51:151-178.
34. Holland JJ, de la Torre JC, Steinhauer DA. RNA virus populations as quasispecies. Curr Top Microbiol Immunol 1992;176:1-20.
35. Eigen M. On the nature of viral quasispecies. Trends Microbiol 1996;4:212-214.
36. Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731-1734.
37. Richman DD, et al. Nevirapine resistance mutations of human immunodeficiency virus type-1 selected during therapy. J Virol 1994;68:1660-1666.
38. Condra JH, et al. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.
39. Mansky LM, Temin HM. Lower in vivo mutation rate of human immunodeficiency virus-type 1 than that predicted from the fidelity of reverse transcriptase. J Virol 1995;69:5087-5094.
40. Wei X, et al. Viral dynamics in human immunodeficiency virus type 1 infection. Nature 1995;373:117-122.
41. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-126.
42. Perelson AS, Neumann AU, Markowitz M, Leonard JM, Ho DD. HIV-1 dynamics in vivo: virion clearance rate, infected cell life-span, and viral generation time. Science 1996;271:1582-1586.
43. Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 1995;267:483-489.
44. Leigh Brown AJ, Richman DD. HIV-1: gambling on the evolution of drug resistance. Nat Med 1997;3:268-271.
45. Havlir DV, Eastman S, Gamst A, Richman DD. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalance in untreated patients. J Virol 1996;70:7894-7899.
46. Molla A, et al. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-766.
47. Shafer RW, et al. Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type-1 strains with unique patterns of pol gene-mutations. J Infect Dis 1994;169:722-729.
48. Shirasaka T, et al. Emergence of human immunodeficiency virus type-1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proc Natl Acad Sci USA 1995;92:2398-2402.
49. Wong JK, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278:1291-1295.
50. Finzi D, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997;278:1295-1300.
51. Borrow P, Oldstone MBA. Lymphocytic choriomeningitis virus. In: Nathanson N, ed. Viral pathogenesis. Philadelphia: Lippincott-Raven; 1997. p.593-627.
52. Phillips AN. Reduction of HIV concentration during acute infection: independence from a specific immune response. Science 1996;271:497-499.
53. Borrow P, et al. Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat Med 1997;3:205-211.
54. Price DA, et al. Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection. Proc Natl Acad Sci USA 1997;94:1890-1895.
55. Butz EA, Bevan MJ. Massive expansion of antigen-specific CD8+ T cells during an acute virus infection. Immunity 1998;8:167-175.
56. Murali-Krishna K, et al. Counting antigen-specific CD8 T cells: a reevaluation of bystander activation during viral infection. Immunity 1998;8:177-187.
57. Callan MFG, et al. Direct visualisation of antigen-specific CD8+ T cells during the primary response to Epstein-Barr virus in vivo. J Exp Med 1998;187:1395-1402.
58. Lewicki H, von Herrath MG, Evans CF, Whitton JL, Oldstone MBA. CTL escape viral variants II. Biologic activity in vivo. Virology 1995;211:443-450.
59. Moskophidis D, Zinkernagel RM. Immunobiology of cytotoxic T-cell escape mutants of lymphocytic choriomeningitis virus. J Virol 1995;69:2187-2193.
60. Gairin JE, Mazarguil H, Hudrisier D, Oldstone MB. Optimal lymphocytic choriomeningitis virus sequences restricted by H-2Db major histocompatibility complex class I molecules and presented to cytotoxic T lymphocytes. J Virol 1995;69:2297-2305.
61. Van der Most RG, et al. Identification of Db and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology 1998;240:158-167.
62. Weidt G, Deppert W, Utermohlen O, Heukeshoven J, Lehmann-Grube F. Emergence of virus escape mutants after immunization with epitope vaccine. J Virol 1995;69:7147-7151.
63. Borrow P, Lewicki H, Hahn BH, Shaw GM, Oldstone MBA. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994;68:6103-6110.
64. Koup RA, et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994;68:4650-4655.
65. Neidermann G, et al. Contribution of proteasome-mediated proteolysis to the hierarchy of epitopes presented by major histocompatibility Class I molecules. Immunity 1995;2:289-299.
66. Heemels MT, Schumacher K, Wonigheit K, Ploegh HL. Peptide translocation by variants of the transporter associated with antigen processing. Science 1993; 262:2059-2063.
67. Shepherd JC, et al. TAP-1-dependent peptide translocation in vitro is ATP dependent and peptide selective. Cell 1993;74:577-584.
68. Chen W, Khilko S, Fecondo J, Margulies DH, McCluskey J. Determinant selection of major histocompatibility complex class I-restricted antigenic peptides is explained by class I-peptide affinity and is strongly influenced by non-dominant anchor residues. J Exp Med 1994;180:1471-1483.
69. Levitsky V, Zhang Q-J, Levitskaya J, Masucci MG. The life span of major histocompatibility complex-peptide complexes influences the efficiency of presentation and immunogenicity of two class I-restricted cytotoxic T lymphocyte epitopes in the Epstein Barr virus nuclear antigen 4. J Exp Med 1996;183:915-926.
70. Tussey LG, et al. Different MHC class I alleles compete for presentation of overlapping viral epitopes. Immunity 1995;3:65-77.
71. Selin LK, Nahill SR, Welsh RM. Cross-reactivities in memory cytotoxic T lymphocyte recognition of heterologous viruses. J Exp Med 1994;179:1933-1943.
72. Siliciano RF, Soloski MJ. MHC class I-restricted processing of transmembrane proteins - mechanism and biological significance. J Immunol 1995;155:2-5.
73. Pantaleo G, et al. Major expansion of CD8+ T cells with a predominant Vb usage during the primary immune response to HIV. Nature 1994;370:463-467.
74. Goulder PRJ, et al. Patterns of immunodominance in HIV-1-specific cytotoxic T lymphocyte responses in two human histocompatibility leukocyte antigens (HLA)-identical siblings with HLA-A*0201 are influenced by epitope mutation. J Exp Med 1997;185:1423-1433.
75. Nietfield W, et al. Sequence constraints and recognition by CTL of an HLA-B27-restricted HIV-1 gag epitope. J Immunol 1995;154:2188-2197.
76. Meyerhans A, et al. In vivo persistence of a HIV-1-encoded HLA-B27-restricted cytotoxic T lymphocyte epitope despite specific in vitro reactivity. Eur J Immunol 1991;21:2637-2640.
77. Harrer T, et al. Cytotoxic T lymphocytes in asymptomatic long-term nonprogressing HIV-1 infection. J Immunol 1996;156:2616-2623.
78. Nowak MA, et al. Antigenic oscillations and shifting immunodominance in HIV-1 infections. Nature 1995;375:606-611.
79. Haas G, et al. Dynamics of viral variants in HIV-1 Nef and specific cytotoxic T lymphocytes in vivo. J Immunol 1996;157:4212-4221.
80. Goulder PJR, et al. Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nat Med 1997;3:212-217.
81. Aebischer T, Moskophidis D, Rohrer UH, Zinkernagel RM, Hengartner H. In vitro selection of lymphocytic choriomeningitis virus escape mutants by cytotoxic T lymphocytes. Proc Natl Acad Sci USA 1991;88:11047-11051.
82. Lewicki H, et al. CTL escape viral variants. I. Generation and molecular characterization. Virology 1995;210:29-40.
83. Oldstone MBA, Lewicki H, Borrow P, Hudrisier D, Gairin JE. Discriminated selection among viral peptides with the appropriate anchor residues: implications for the size of the cytotoxic T-lymphocyte repertoire and control of viral infection. J Virol 1995;69:7423-7429.
84. Perlman S, Schelper R, Bolger E, Ries D. Late onset, symptomatic, demyelinating encephalomyelitis in mice infected with MHV-JHM in the presence of maternal antibody. Microb Pathog 1987;2:185-194.
85. Castro RF, Perlman S. CD8+ T cell epitopes within the surface glycoprotein of a neurotropic coronavirus and correlation with pathogenicity. J Virol 1995;69:8127-8131.
86. Pewe L, Wu GF, Barnett EM, Castro RF, Perlman S. Cytotoxic T cell-resistant variants are selected in a virus-induced demyelinating disease. Immunity 1996;5:253-262.
87. Perlman S, Pewe L. CTL escape mutants cause increased mortality and morbidity in mice infected with mouse hepatitis virus, strain JHM. Keystone Symposium on Molecular Aspects of Viral Immunity; 1998 Feb 16-22; Tamarron (CO). p. 72.
88. Rickinson AB, Lee SP, Steven NM. Cytotoxic T lymphocyte responses to Epstein-Barr virus. Curr Opin Immunol 1996;8:492-497.
89. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997;15:405-431.
90. De Campos-Lima PO, et al. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med 1994;179:1297-1305.
91. Burrows JM, Burrows SR, Poulsen LM, Sculley TB, Moss DJ, Khanna R. Unusually high frequency of Epstein-Barr virus genetic variants in Papua New Guinea that can escape cytotoxic T-cell recognition: implications for virus evolution. J Virol 1996;70:2490-2496.
92. Lee SP, et al. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population. Eur J Immunol 1995;25:102-110.
93. Chisari FV, Ferrari C. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995;13:29-60.
94. Bertoletti A, et al. Cytotoxic T lymphocyte response to a wild-type hepatitis B virus epitope in patients chronically infected by variant viruses carrying substitutions within the epitope. J Exp Med 1994;180:933-943.
95. Rehermann B, Pasquinelli C, Mosier SM, Chisari FV. Hepatitis B virus (HBV) sequence variation in cytotoxic T lymphocyte epitopes is not common in patients with chronic HBV infection. J Clin Invest 1995;96:1527-1534.
96. Ferrari C, Bertoletti A, Fiaccadori F, Chisari FV. Is antigenic variability a strategy adopted by hepatitits B virus to escape cytotoxic T-lymphocyte surveillance? Semin Virol 1997;7:23-30.
97. Houghton M. Hepatitis C viruses. In: Fields BN, ed. Fields virology. Vol. 1. Philadelphia: Lippincott-Raven Publishers, 1997. p.1035-1058.
98. Walker CM. Cytotoxic T-lymphocyte responses to the hepatitis C virus in humans and chimpanzees. Semin Virol 1996;7:13-21.
99. Weiner A, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci USA 1995;92:2755-2759.
100. Erickson AL, et al. Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis C. J Immunol 1993;151:4189-4199.
101. Walker DB, et al. HIV specific cytotoxic T lymphocytes in seropositive individuals. Nature 1987;328:345-348.
102. Plata F, et al. AIDS virus specific cytotoxic T lymphocytes in lung disorders. Nature 1987;328:348-351.
103. Rinaldo C, et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J Virol 1995;69:5838-5842.
104. Klein MR, et al. Kinetics of Gag-specific cytotoxic T lymphocyte responses during the clinical course of HIV-1 infection: a longitudinal analysis of rapid progressors and long-term asymptomatics. J Exp Med 1995;181:1365-1372.
105. Bevan MJ, Braciale TJ. Why can't cytotoxic T cells handle HIV? Proc Natl Acad Sci USA 1995;92:5765-5767.
106. Jassoy C, Walker BD. HIV-1-specific cytotoxic T lymphocytes and the control of HIV-1 replication. Springer Semin Immunopathol 1997;18:341-354.
107. Pantaleo G, et al. Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proc Natl Acad Sci USA 1997;94:9848-9853.
108. Rosenberg ES, et al. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997;278:1447-1450.
109. Oldstone MBA. HIV versus cytotoxic T lymphocytes - the war being lost. N Engl J Med 1997;337:1306-1308.
110. Klenerman P, Zinkernagel RM. What can we learn about human immunodeficiency virus infection from a study of lymphocytic choriomeningitis virus? Immunol Rev 1997;159:5-16.
111. Collins KL, Chen BK, Kalams SA, Walker BD, Baltimore D. HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391:397-401.
112. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
113. Phillips RE, et al. Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition. Nature 1991;354:453-459.
114. Koenig S, et al. Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat Med 1995;1:330-336.
115. Mortara L, Letourneur F, Gras-Masse H, Venet A, Guillet J-G, Bourgault-Villada I. Selection of virus variants and emergence of virus escape mutants after immunization with an epitope vaccine. J Virol 1998;72:1403-1410.